EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSOKIG00005022541
Gene Symbol: KCNQ2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSOKIG00005044400
Gene Symbol: KCNQ2
3 Cross references
179 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSOKIG00005048636
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSOKIG00005041109
Gene Symbol: KCNQ5
3 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSOKIG00005018044
Gene Symbol: KCNH2A
1 Cross references
150 Possible Orthologues:

Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 3-Like

Ensembl ID : ENSOKIG00005036187
Gene Symbol: LOC109898259
2 Cross references
208 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSOKIG00005013450
Gene Symbol: LOC109901819
3 Cross references
176 Possible Orthologues:

Presenilin-2-Like

Ensembl ID : ENSOKIG00005026693
Gene Symbol: LOC109890007
3 Cross references
200 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSOKIG00005002934
Gene Symbol: LOC109898551
2 Cross references
409 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSOKIG00005028152
Gene Symbol: LOC109907126
3 Cross references
248 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSOKIG00005034096
Gene Symbol: LOC109904367
3 Cross references
248 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSOKIG00005027748
Gene Symbol: LOC109883924
3 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).